Defining Digital Solutions
for Unmet Medical Needs

DTxDM West – San Jose, CA – Feb 27th-28th, 2018


DTxDM East – Boston, MA – Sept 25th – 26th, 2018

The next generation of healthcare is digital. At the recent DTxDM summit in San Jose, over 120 pioneers and future players of this exciting new industry came together to accelerate the development of scientifically-validated digital treatments.

DTxDM East takes place in Boston, MA on September 25-26, 2018.
Building on the success of the West coast event this event will sell out.

Pre-launch bookings for DTxDM East are now being accepted. Please see the registration page for details.

You can review the West coast event on this site.  Details for the East Coast event will be published shortly.  If you would like to get involved, please send us a message via the enquiry form on the registration page.


Key Aims of the Summit

Define & Construct

Defining the foundations of this emerging industry and building the ecosystem required to penetrate the healthcare paradigm.

Understand & Overcome

Deciphering scientific and commercial challenges to construct strategies for accelerating the adoption and application of new treatments.

Network & Collaborate

Bringing together digital medicine companies, pharma and investors to form new partnerships and investment opportunities.

Is The Event For You?

With healthcare becoming more expensive and smart devices more prevalent, digital medicine and digital therapeutics are seeking to improve patients’ lives through validated digital approaches. At this crucial point of rapid adoption, the Digital Therapeutics and Digital Medicine Summit will provide the first industry-dedicated forum to advance this new generation of healthcare.

The Digital Therapeutics and Digital Medicine Summit will serve digital therapeutic & digital medicine companies, pharma and investors who are developing digital solutions for patients in need. Specifically designed for those looking to drive forward this new treatment paradigm, the summit will address the leading scientific, tech and commercial challenges in this rapidly emerging field.

An exec-level gathering for the pioneers and future players in the industry, the Digital Therapeutics and Digital Medicine Summit will aid in defining the foundations of the field, as well as its future direction. Promoting openness and collaboration, the summit will yield genuine insights, idea sharing and investment conversations to capitalize on the potential of this digital revolution.

The Digital Therapeutics and Digital Medicine Summit will bring together the key stakeholders in the industry to connect, share knowledge and define the future of the field.

Who You Will Learn From


Seth Feuerstein

CIO & CMO, Medical & Digital Innovation, Magellan Health

Seth Feuerstein is the chief medical officer of medical and digital innovation at Magellan Healthcare. In this role, he leads the development of effective business and clinical programs that leverage technology in several areas. Feuerstein, a psychiatrist by training, most recently developed Cobalt, a virtual therapeutic program which addresses 90 percent of behavioral health disorders. Feuerstein developed this virtual care platform to achieve better health, better care, and lower costs. With its acquisition of Cobalt, Magellan helps clients deliver online cognitive behavioral therapy to address problems such as anxiety, insomnia, depression, OCD and substance abuse.

Pierre Leurent

CEO, Voluntis

Pierre Leurent, CEO and founder of VOLUNTIS, has more than 19 years of international experience in digital health in the United States and Europe. Voluntis’ mission is to improve the real-world value of therapies by providing patients and clinicians with therapeutic companion software. Its clinical-grade, regulatory-cleared mobile and cloud solutions embed advanced real-time decision support algorithms to enable patients to better manage their treatment in remote collaboration with their healthcare team. Prior to starting Voluntis in 2001, Pierre worked at GE Medical Systems, where he took part in the development of medical imaging software. He also occupied several positions at HealthCenter Internet Services, a San Francisco-based vendor of electronic medical record solutions.

Peter Hames

Co-Founder & CEO, Big Health

Peter Hames is co-founder and CEO of Big Health, a company creating “digital medicine” - automated, digital, behavior change programs for mental health that are as scalable as drugs yet as effective as in person therapy. Peter is an NHS Innovation Fellow, and holds a Masters in Experimental Psychology from Oxford University. It was his own experience of insomnia, and how he overcame it, that inspired him to found Big Health and create Sleepio, a digital sleep improvement program that is now available to over 1 million employees as part of their benefits package.

Dan Karlin

Head, Clinical, Informatics & Regulatory Strategy, Digital Medicine, Pfizer

Dan is the Head of Clinical, Informatics, and Regulatory Strategy for Digital Medicine and Pfizer Innovation Research Lab, where he manages strategy for multiple aspects of Pfizer's collaborative digital measurement and endpoint development efforts. Digital Medicine ensures that asset teams have access to and an understanding of the value that digital measurement can bring to the clinical development paradigm. He is active in the mobile sensing space, investigating technologies, their applicability to drug development, and rational pathways for their validation and integration. He develops and executes strategies for data management, analysis, and interpretation for projects and programs throughout the company. Dan is board certified in Psychiatry, Clinical Informatics, and Addiction Medicine, and is an Assistant Professor of Psychiatry at Tufts University School of Medicine. Dan received his BA in Neuroscience and his MA in Medical Informatics from Columbia University; his MD from the University of Colorado, School of Medicine; and trained in psychiatry at Tufts Medical Center.

LeRoux Jooste

Chief Commercial Officer, Akili Interactive Labs

LeRoux is a Pharma/Biotech executive with global experience in senior leadership positions. Most recently he served as Chief Commercial Officer and Senior Vice President, Business Development at Ocata Therapeutics. He previously held executive positions at Antares Pharma, Cephalon, Wyeth and Eli Lilly. LeRoux has led the commercialization and launch of several innovative products including Enbrel™, Otrexup™ and Prozac™. He graduated from Pharmacy School and obtained his Bachelor of Commerce degree in South Africa.

Albert Chan

Vice President, Chief of Digital Patient Experience, Sutter Health

Albert Chan, M.D., M.S., FAAFP, as Vice President, Chief of Digital Patient Experience at Sutter Health, is the corporate champion for the transformation of web and mobile health care services, translating the latest advancements in digital health into consumer-centric patient experiences and digitally empowered clinician workflows. He also leads the Sutter Health My Health Online initiative. He practices in Family Medicine at the Palo Alto Medical Foundation. Dr. Chan earned a bachelor's degree with honors in Biological Sciences from Stanford University and a medical degree from the University of California, San Diego School of Medicine. He completed his residency and year as chief resident in family medicine at the San Jose Medical Center Family Practice Residency, affiliated with Stanford University of School of Medicine. He concurrently completed a postdoctoral fellowship in Biomedical Informatics at Stanford University School of Medicine and Family Medicine Research at the University of California, San Francisco School of Medicine, studying the effects of point of care decision support in the management of hypertension. During fellowship, Dr. Chan also assisted with the launch of PAMFOnline, now Sutter's My Health Online, one of the earliest PHRs in the United States.

Kristian Ranta

CEO & Founder, Meru Health

Kristian Ranta is a serial entrepreneur and a musician. He is currently CEO & Founder of Meru Health, a ‘digital therapeutics for depression” –startup company. Previously he was the CEO & Founder of Mendor, a diabetes technology company. Part of Mendor was sold to a Korean public company in 2015. Kristian resigned from Mendor in fall 2015 to found Meru Health. Kristian’s eldest brother committed suicide in 2005 and now with Meru Health, Kristian wanted to start helping other people like him who are suffering from depression. Kristian’s passion is to build global businesses that improve healthcare and how it’s been delivered. He believes in humane values, positivity and the importance of reducing suffering in the world.

Kevin McRaith

CEO, WellDoc

As CEO, Kevin has led the WellDoc® team in the successful launch and continued development of the digital therapeutic for people living with type 2 diabetes, BlueStar®. Under his leadership, WellDoc has expanded its suite of BlueStar products to include: BlueStar® Rx, BlueStar® and BlueStar® C. Kevin oversees all WellDoc business related to enterprise strategy and has engineered an innovative commercial approach to position BlueStar in the marketplace to attract key investors and partnerships that include, Johnson & Johnson, Samsung and Merck GHI.

John Spinale

General Partner, Jazz Venture Partners

John currently is an investor and active advisor to many early-stage companies, in areas ranging from virtual reality (VR) platforms and content publishers to digital health apps for diagnosing and treating cognitive conditions like ADHD. John was most recently the General Manager of Disney’s (DIS) mobile and social games division, where he launched many chart topping titles while handling the full P&L for this multi-hundred million dollar business. John brings a deep understanding of creating innovative consumer experiences, building brands and leveraging new and emerging platforms to JAZZ. He is a proven leader in consumer technology and digital media with a career spanning nearly 20 years of building, scaling and running high-growth companies of all sizes, from initial seed through to late stage.

Jesse Bridgewater

VP, Data Science, Livongo

Gabriel Vargas

Executive Medical Director, Mobile Health, Amgen

After leaving academia in 2006 he spent five years at Roche the last 3 in Basel, Switzerland as head of the Neuroscience Biomarker Group where Gabriel worked on biomarkers including digital approaches. He joined Amgen in 2011 and leads a group of physician-scientists in Neuroscience and heads the Digital Health activities in Medical Sciences. He co-leads Amgen’s Clinical Technology & Experience Lab and has conducted several digital health studies to test wearable sensors and devices and patient engagement technologies.

Elli Kaplan

CEO, Neurotrack

Elli Kaplan is the co-founder and CEO of Neurotrack. Her career spans two decades in the public and private sectors, including at the White House, State and Treasury Departments, and the United Nations. Elli has also held positions with AIG, Goldman Sachs and multiple startups. She has won the San Francisco Business Chronicle’s Most Influential Women in the Bay Area award, SXSW's best new startup and DEMO God awards, the J&J World Without Disease Challenge, and presented at Code, Fortune Health, TEDx, TechCrunch Disrupt, the Royal Society of Medicine, Wired and the New York Times. Elli has an M.B.A. from Harvard Business School.

Edward Cox

CEO, Dthera Sciences

Edward Cox was appointed as the new Chairman of the Board and the Chief Executive Officer of Dthera in connection with the closing of the EveryStory Transaction. Mr. Cox also continues to serve as EveryStory’s President and Chief Executive Officer and Chairman and a member of EveryStory’s Board of Directors, positions he has held since February 6, 2015. Prior to that, he served as a Vice President and Executive Officer of Apricus Biosciences, Inc., a publicly traded company, since December 2009, in roles leading Commercial Development, Business Development, Investor Relations, and Corporate Development. Mr. Cox holds a Master of Science in Management degree from the Warrington College of Business Administration at the University of Florida.

Eddie Martucci

CEO, Akili Interactive Labs

Eddie co-founded Akili Interactive Labs, and as part of PureTech has co-founded two other health-focused start-ups, and helped launch their digital health initiative. He was previously a Kauffman Entrepreneur Fellow, a program sponsored by the Kauffman Foundation of Kansas City, MO, focused on healthcare entrepreneurship. Prior to that, he completed his graduate work at Yale University in the Departments of Pharmacology and Molecular Biophysics & Biochemistry, focusing on structure-based drug design, where he led a research project that identified two novel chemical scaffolds as proof-of-concept compounds for novel therapy. Eddie received his B.S. in Biochemistry from Providence College, and his M.Phil. and Ph.D. from Yale University.

Debbie Profit

VP, IT, Otsuka Pharmaceuticals

Deborah Profit has worked in pharmaceutical industry for over two decades and is currently the Vice President, Otsuka Information Technology (OIT) at Otsuka Pharmaceuticals. In this role, Dr. Profit is responsible for the commercial, enterprise and research and development arms of the Otsuka IT organization. In her current role, Dr. Profit is responsible for the executive sponsorship of creative solutions across technical, commercial and clinical development teams. Dr. Profit also plays a key leadership role in transitioning pilots and prototypes to full-scale projects to leverage solutions globally that complement the business portfolio to include digital medicine, digital health and big data platforms. Dr. Profit possesses undergraduate degrees in nursing and psychology, a Master of Science in Regulatory Affairs - Drugs, Biologics and Medical Device, and a Doctorate in Leadership Studies with a concentration in Innovation and Creativity.

David Van Sickle

CEO & Co-Founder, Propeller Health

David Van Sickle is CEO and Co-Founder of Propeller Health. David was formerly an Epidemic Intelligence Service Officer with the Centers for Disease Control and Prevention, and a Robert Wood Johnson Foundation Health and Society Scholar at the University of Wisconsin School of Medicine and Public Health. He writes about asthma epidemiology, medical anthropology, and global chronic respiratory disease at

David Klein

CEO, Click Therapeutics

David Benshoof Klein is a healthcare investor and entrepreneur with over 15 years life science industry experience; he has played key roles in founding, financing and operating more than 10 life science companies. In 2012, Mr. Klein co-founded Click Therapeutics which develops and commercializes software as medical treatments: Digital TherapeuticsTM. Click's lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults. He formerly served as Managing Director at Opus Point Partners, senior consultant to Pfizer, and strategic advisor to numerous publicly traded and privately held life science companies. Mr. Klein holds a B.A. from Brandeis University and has been a guest lecturer at Columbia University’s Biotechnology Program.

David Kim

CEO, DigiTx Partners

David is the CEO of DigiTx Partners, bringing both business and clinical expertise to venture capital with an extensive background practicing medicine and building healthcare software companies. Most recently, Dr. Kim served as the COO of Lumiata, a venture-backed predictive analytics company positioned at the intersection of data science and medical science. Prior to Lumiata, he spent over a decade as an investor evaluating and growing healthcare companies at MPM Capital and Pinnacle Ventures. Before entering the business sector, David practiced as a general internist and hospitalist at Kaiser South San Francisco where he also served as the Director of Urgent Care and Assistant Chief of Internal Medicine.

Alex Waldron

Chief Commercial Officer, Pear Therapeutics

Alex is a senior level global bio/pharmaceutical business leader with 27+ years of experience with large pharmaceutical, fully integrated biopharmaceutical and startup organizations. He has a proven record of building and leading business strategy and operations. In his career, Alex has driven enterprise value from portfolio strategy through to commercial launch. In previous roles, Alex has architected the structure and growth of several divisions at Biogen and helped to shape the emerging biosimilar market at Epirus Biopharmaceuticals. Alex has also worked in numerous commercial and operations roles at Genzyme, Astra Zeneca, Pfizer and Bristol-Myers Squibb.

Bozidar Jovicevic

VP, Global Head of Digital Medicines, Sanofi

Bozidar Jovicevic is a Global Head of Digital Medicines at Sanofi, in charge for beyond-the-drug initiatives. He is MD/MBA by training and during the first part of his career he spent 12 years at Novartis in various sales and marketing roles, launching two multi-billion dollar products on a regional and global level. He then moved to a medical function where he orchestrated transformation of multichannel engagement with HCPs through building VivindaTV, a global eCongress platform dubbed as “Netflix of medical conferences” (currently available in 104 countries).

Ravi Gopalakrishnan

Head of Mobility, CTO Office, MedImmune

Curtis Duggan

Co-Founder & CEO, Blue Mesa Health

Curtis Duggan is the CEO and Co-Founder of Blue Mesa Health. Coming from a background as an agency owner in the field of technology, mobile product development, and user experience design, Curtis is now tackling one of the world’s most pressing health problems: the burden posed by lifestyle-related and chronic disease. While co-founding and running Dactyl Studios, his British Columbia-based mobile app agency, for four years, Curtis saw firsthand how profoundly the mobile and cloud revolutions were transforming various industries in the early 2010s. However, he observed that the health care industry in particular was not leveraging advances in technology and experience design with the same velocity as other industries. In 2015, he decided to dedicate his life to addressing the global chronic disease burden by partnering with co-founders and investors to co-create Blue Mesa Health, a digital health company with a mission to provide chronic disease prevention solutions in the USA and internationally.

Scott Honken

SVP, Payer Sales & Strategy, Voluntis

Scott Honken currently serves as the Senior Vice President of Payer Sales & Strategy and member of Voluntis’ Leadership Team. Scott is accountable for securing coverage, obtaining reimbursement, and driving utilization of Voluntis’ FDA-cleared digital solutions by health plans, pharmacy benefit managers, integrated delivery systems, and provider groups. He brings a proven track record of forming and growing payer relationships, a passion for digital health, and a strategic vision for the future of value-based contracting to his work at Voluntis.

Michelle Marlborough

Chief Product Officer, Healthcare, AiCure

As Chief Product Officer at AiCure, Michelle Marlborough is responsible for the product direction, definition and delivery of the company’s award winning artificial intelligence platform for medication adherence and management. With over 18 years of experience in life sciences and software development, Michelle has been at the forefront of transforming clinical trials through innovative technology and analytics and previously held the positions of Vice President of Product Management at Veeva and Vice President of Product Strategy at Medidata Solutions.

Everett Crosland

Head of Market Access & Reimbursement, Pear Therapeutics

Everett is the Head of Market Access & Reimbursement with Pear Therapeutics, a digital therapeutics company located in Boston, Massachusetts. At Pear, Everett leads payer strategy and engagement, pricing, reimbursement, HEOR, and government affairs. In past roles he has led the launch readiness and market access and reimbursement commercialization of infused, oral, drug-device combination, and digital therapies, and he has extensive experience managing pricing, payer, and reimbursement diligence for in-licensing, out-licensing, and buy-outs.

Sean Duffy

Co-Founder & CEO, Omada Health

Sean Duffy is the co-founder and CEO of Omada Health, a digital behavioral medicine company dedicated to inspiring and empowering people everywhere to live free of chronic conditions like heart disease and type 2 diabetes. In 2016, Omada was named a Technology Pioneer by the World Economic Forum, and in 2015 and 2017, the company was recognized as one of Fast Company’s Most Innovative Companies. Prior to Omada, Sean worked at both Google and IDEO. A former MD/MBA candidate at Harvard, he holds a BS in neuroscience from Columbia University.

Adam Kaufman

President & CEO, Canary Health

Adam Kaufman is a health pioneer, having led the building of digital behavior change programs used by dozens of healthcare organizations and tens of thousands of consumers. A health economist, engineer and company executive, Adam speaks to audiences nationwide on the accelerating trend of chronic illness, its impact on lives and costs of care and proven approaches to arresting disease trajectories.
Recognized as a leader in patient engagement and population health, Canary Health works with health plans such as Kaiser Permanente, Humana, GEHA and Blue Shield of California to empower members to better health self-management.

Aaron Nelson

General Partner, dRx Capital

Aaron is a General Partner at dRx Capital, as well as a Strategic Project Leader within the Trials of The Future team of Novartis Pharmaceuticals. In recent years, Aaron has worked on technology strategy for clinical trial teams within Novartis. This work has led him to conclude that mobile, cloud, and Health IT technologies provide transformative opportunities in the clinical research and pharmaceutical industries. Aaron has led projects building upon these themes across multiple Business Units within Novartis, often by collaborations or investments in early-stage partner companies. Previously, Aaron led laboratory teams at Novartis, investigating the biological bases for drug toxicity. Aaron studied medicine at Tufts University, cell and microbiology at the University of Pennsylvania and the Karolinska Institute, and completed his undergraduate studies at Cornell University.

Joe Powers

Managing Director, Healthcare, Headspace

Joe Powers is Managing Director, Healthcare at Headspace where he is responsible for healthcare strategy and partnerships. Prior to Headspace, Joe served as Head of Commercialization, inHealth and Director of Business Development for Johns Hopkins Technology Ventures, where he focused primarily on establishing digital health corporate partnerships across Johns Hopkins University, Hospitals, and Health System. Joe has nearly 20 years of experience developing business, marketing, and commercial strategies and programs for prominent for-profit and non-profit organizations around the world.

Ahmed Albaiti

Founder & CEO, Medullan

A hands-on leader and a strategic thought leader who helps his clients create truly connected experiences by integrating marketing, technology, and traditional communication. He serves as executive client counsel on digital health strategy. Ahmed is also an active speaker and thought leader, having spoken at various events such as HIMSS, the Center for Connected Health Symposium, and AHIP. His perspectives on the future of health and digital healthcare has been featured in the media including USA Today, Inc., STATNews, mHealth News, LinkedIN and MedTech Boston.

Jeff Gombala

Managing Partner, Medullan

Jeff is responsible for growing Medullan’s business by designing, developing and promoting the adoption of innovative, high-impact digital solutions for our clients. A champion of human centric design, Jeff brings over 15 years of experience of agile and lean startup methodologies for service design and solution development to deliver high impact digital solutions spanning diverse domains such as healthcare, financial, military/defense, and mortgage industries. Work at Medullan has included the design of Patient Support Programs, Coordinated Care Platforms, and digital experiences for Larger Payers. As Client Partner on these engagements, Jeff brings hands on leadership to multidisciplinary teams exceeding client expectations.

Ryan Rossier

General Manager, Platform Solutions, Medullan

Ryan heads up Medullan's Platform Solutions team, where he is responsible for R&D and go-to-market strategies for Medullan's suite of products, including our care experience platform, VARA. He is an internationally experienced health innovator with over 15 years of experience applying technology to solve business problems. Ryan practics lean start-up, human-centered design, and agile software development principles to create pragmatic solutions which people adopt and use. A hands-on leader, Ryan enjoys building highly productive, collaborative, and innovative teams by aligning people and process. Ryan has collaborated with clients across the healthcare spectrum, including Aetna, Boehringer Ingelheim, Nestle Health Science, WebMD, and Anthem.

Brent Vaughan

CEO & Co-Founder, Cognoa

Brent is the CEO and co-founder of Cognoa, an AI-based digital precision medicine behavioral health platform. Cognoais developing innovative digital diagnostics and digital therapeutics to change the standard of care for pediatric behavioral health and improve outcomes by enabling earlier diagnosis, treatment, and increased engagement. Brent has over 20 years industry experience working with diagnostics, therapeutics and digital consumer health. Prior to Cognoa, Brent was the co-founder and COO of WellnessFX, an award-winning digital health company that increased patient engagement by providing direct-to-consumer diagnostics and integrated telemedicine. Before working in digital health, Brent worked in product and commercial roles in Novartis, Nektar, Roche and Lily.

Kal Patel

SVP, Digital Health, Flex Digital Health

David Amor

VP, Quality & Regulatory Affairs, Pear Therapeutics

David Amor is an FDA/ EU Quality/ regulatory expert focused on combination products and digital health. From NDAs and 505(b)(2)s to mobile app 510(k)s and Pre-INDs/ Q-subs, David has worked with over 45 medical device and pharmaceutical companies – large and small alike- supporting and/ or leading regulatory submissions and implementing quality management systems, including alignment of Agile-based SDLC programs to FDA and EU requirements. He co-founded RemindTrac in 2014 (, a digital health company for chronic patients, that continues to pioneer mobile care management systems today, and sold his consulting firm Medgineering in 2016.

David has recently led QA/RA strategy groups at Teva within the Digital Health Group, particularly in development of Agile-based Quality Management Systems, was a Principal Consultant in the CP/DH (Combination Products, Digital Health) group at Qara Partners, and served as the in-house risk management subject matter expert at Abbott (St. Jude Medical). He has served as the Director or VP of Quality at other medical device start-ups including AdrenaCard, Calcula, Enspero Medical and various others, and led multiple organizations through 483 and Warning Letter remediation projects, namely associated with risk management and design history file deficiencies, including Pfizer (Hospira), MID, Boston Scientific and St. Jude Medical.

Dave Keene

Chief Technology Officer, Dthera Sciences

David Keene was appointed as Dthera's Chief Technology Officer and a member of Dthera's Board of Directors in connection with the EveryStory Transaction. Mr. Keene, the founder of EveryStory and a member of EveryStory's Board of Directors, is a veteran of the video game industry who has specialized in commerce and content delivery. Prior to founding EveryStory, from 2010 to 2013, Mr. Keene served as Chief Architect - Commerce Platform for Trion Worlds, Inc. (fka Trion World Networks, Inc.).

What Will I Learn?

Download Agenda

Click to download our full event agenda.

8:00    Registration, Breakfast & Networking
9:00    Chairman’s Opening Remarks & Setting the Scene

David Klein, Chief Executive Officer, Click Therapeutics

9:10     How are Digital Therapeutics Pioneers Joining Forces to Establish this New Industry Sector?

Pierre Leurent, Chief Executive Officer, Voluntis

9:25     Applying AI to Create Digital Precision Medicine in Behavioural Health

Brent Vaughan, Chief Executive Officer & Co-Founder, Cognoa

9:50    Keynote Panel and Open Q&A: Digital Therapeutics – An Assessment of the Leading Hurdles and Opportunities

Peter Hames, Co-Founder & Chief Executive Officer, Big Health
Elli Kaplan, Chief Executive Officer, Neurotrack
Eddie Martucci, Chief Executive Officer, Akili Interactive Labs
Alex Waldron, Chief Commercial Officer, Pear Therapeutics

10:30    Speed Networking & Morning Refreshments
Research Showcase – What is Being Achieved with Digital Medicine and Digital Therapeutics?
11:15    Digital Interventions as Diabetes Management Programs

Jesse Brigewater, Vice President, Data Science, Livongo

11:40    Digital Therapeutics for Chronic Disease Prevention

Sean Duffy, Co-Founder & Chief Executive Officer, Omada Health

12:05    Digital Medicines and the Personal Future of Care and Treatment for Chronic Respiratory Disease

David Van Sickle, Chief Executive Officer & Co-Founder, Propeller Health

12:30   After the Endpoint: How Digital Medicine Can Transcend Traditional Research Standards

Peter Hames, Co-Founder & Chief Executive Officer, Big Health

12:55   Leveraging ML/AI to Deliver a New Level of Intelligence to Digital Therapeutics

Kal Patel, Senior Vice President, Digital Health, Flex Digital Health

1:20    Networking Lunch
2:20    Collaborative Workshops:
Workshop 1
Overcoming the Start-up Challenges When Building a Digital Therapeutic Company

Dave Keene, Chief Technology Officer, Dthera Sciences

Workshop 2
Meeting the Challenges of Developing Digital Therapeutics

Ahmed Albaiti, Founder & Chief Executive Officer, Medullan
Jeff Gombala, Managing Partner, Medullan
Ryan Rossier, General Partner, Platform Solutions, Medullan

Workshop 3
Understand the Current and Likely Future Regulatory Landscapes for Digital Health

David Amor, VP, Quality & Regulatory Affairs, Pear Therapeutics

3:20    Afternoon Refreshments
Decisive Debates on Commercialization
4:00    Panel Discussion and Open Q&A: How are Different Business Models Driving the Short-Term and Long-Term Commercial Viability of Digital Therapeutics?

Edward Cox, Chief Executive Officer, Dthera Sciences
LeRoux Jooste, Chief Commercial Officer, Akili Interactive Labs
John Spinale, General Partner, Jazz Venture Partners
Brent Vaughan
, CEO & Co-Founder, Cognoa

4:45    Panel Discussion and Open Q&A: What is the Best Practice for Partnerships to Advance Digital Therapeutics and Digital Medicine?

Bozidar Jovicevic, Vice President, Global Head of Digital Medicines Sanofi
Dan Karlin, Head, Clinical, Informatics & Regulatory Strategy, Digital Medicine, Pfizer
Michelle Marlborough, Chief Product Officer AiCure
Gabriel Vargas, Executive Medical Director, Mobile Health & Neuroscience TA Head Amgen

5:30    Therapeutic Interventions – Drink Reception
Download Agenda to access full details of the event…
Download Agenda
8:00    Breakfast & Networking
9:00   Chair’s Opening Remarks

Edward Cox, Chief Executive Officer, Dthera Sciences

Decisive Debates on Outcomes and Reimbursement
9:10     Panel Discussion and Open Q&A: What are the Best Practices for Utilizing Real World Evidence and Data Outcomes for Digital Therapeutic and Digital Medicine Adoption?

Albert Chan, Vice President & Chief of Digital Patient Experience Sutter Health
Curtis Duggan, Co-Founder & Chief Executive Officer Blue Mesa Health
Ravi Gopalakrishnan, Head of Mobility, CTO Office AstraZeneca
Kristian Ranta, Chief Executive Officer & Founder Meru Health

9:55    Panel Discussion and Open Q&A: How are we Going to Overcome the Crucial Hurdles for Digital Therapeutic Reimbursement?

Seth Feuerstein, Chief Innovation Officer & Chief Medical Officer, Medical & Digital Innovation, Magellan Health
Scott Honken, Senior Vice President, Payer Sales & Strategy, Voluntis
Kevin McRaith, Chief Executive Officer, WellDoc
Everett Crosland, Head, Market Access & Reimbursement Pear Therapeutics

10:40   Morning Refreshments
Research Showcase – What is Being Achieved with Digital Therapeutics and Digital Medicine?
11:20    Improving Neural Functioning and Treating Cognitive Symptoms with Digital Platforms

Eddie Martucci, Chief Executive Officer Akili Interactive Labs

11:50    Targeting Multiple Indications with a Digital Therapeutics Platform

David Klein, Chief Executive Officer Click Therapeutics

12:20    Case Study: Leveraging Wearables in the Clinical Trial Process in Patients with Mental Illness

Debbie Profit, Vice President, Information Technology Otsuka Pharmaceuticals

12:50    Network Lunch
Shaping the Future of the Industry
2:00    Panel Discussion and Open Q&A: Shaping the Future of Digital Therapeutics and Digital Medicine

Adam Kaufman, President & Chief Executive Officer Canary Health
David Kim, Chief Executive Officer DigiTx Partners
Aaron Nelson, General Partner dRx Capital
Joe Powers, Managing Director, Healthcare Headspace

2:50    Chairman’s Summary

Edward Cox, Chief Executive Officer Dthera Sciences

3:00    Close of the Digital Therapeutics & Digital Medicine Summit 2018
Download Agenda to access full details of the event…
Download Agenda

The Venue

Fairmont Luxury Resort & Spa . San Jose

The summit is being held in the Fairmont, San Jose. Located in the heart of Silicon Valley in Northern California, this 20-story luxury hotel is the perfect venue for the 2018 summit.

The conference rooms are designed to provide the optimum environment for learning and collaborating, with plenty of space for meetings, conversations or just time to reflect and catch-up.

After a full day, you can relax in the roof top pool, make full use of the leisure facilities or just relax in the bars and restaurants.



We believe that all business deals start with a conversation. Our summits provide the perfect opportunity to have longer, meaningful conversations. Whether you want to simply connect with our audience or showcase thought leadership, we will work with you to develop a solution that meets your objectives and budgets.

With over 40 years collective experience in the conference industry, we know how to deliver for our sponsors. With a reputation for honesty, you will find our lack of hyperbole and over-promise a refreshing and welcome change.

It starts with a conversation! To find out more, please contact Nick for a no-obligation initial discussion.

Contact Us

Register For The Event

For pricing and booking options please click the button to go to the registration page.